Everence Capital Management’s Integra LifeSciences IART Stock Holding History

Everence Capital Management’s Portfolio IART Stock Details IART Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-5,310	Closed	-$294K	–	437
2018 Q1	$294K	Hold	5,310	–	–	0.07%	305
2017 Q4	$254K	Hold	5,310	–	–	0.06%	347
2017 Q3	$268K	Hold	5,310	–	–	0.06%	302
2017 Q2	$289K	Hold	5,310	–	–	0.07%	294
2017 Q1	$224K	Buy	+5,310	New	+$227K	0.06%	318

Other funds holding IART

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Everence Capital Management's IART Position: Q2 2018 in Review

Everence Capital Management sold out of Integra LifeSciences (IART) in Q2 2018, closing a stake of 5,310 shares — an estimated $294K sold.

Everence Capital Management first reported a position in IART in Q1 2017 and held it in 5 quarters. The position peaked at $294K in Q1 2018. 257 funds tracked by Wall St. Rank hold IART as of Q2 2018.

Everence Capital Management reported no remaining Integra LifeSciences position as of Q2 2018 after selling out during the quarter.
Everence Capital Management sold 5,310 Integra LifeSciences shares in Q2 2018, an estimated $294K.
Everence Capital Management first reported a position in Integra LifeSciences in Q1 2017 and held it in 5 quarters.
Everence Capital Management's Integra LifeSciences position peaked at $294K in Q1 2018.
257 funds tracked by Wall St. Rank held Integra LifeSciences as of Q2 2018.

Based on Everence Capital Management's 13F filing for Q2 2018, filed 26 Jul 2018.